Antibody Drug Conjugate Market Research Report – Forecast to 2027

Antibody Drug Conjugate Market: By Types (Monoclonal Antibodies, Linker), Product (Adcertis, Kadcyla) Technology (Immunogen Technology, Immunomedics Technology), Applications (Leukemia, Lymphoma) End-Users (Biotechnology Companies) - Forecast 2027

ID: MRFR/Pharma/0607-HCR | February, 2021 | Region : Global

Antibody Drug Conjugate Market Scenario


Antibody drug conjugates comprise three parts, mainly a specific antibody for binding, a cytotoxic agent designed to kill target cancer cells, and a chemical linker for attaching the cytotoxic agent to the antibody. These drug conjugates are regarded to be the new age of therapeutic agents. The combine effect of targeting specific types of cells and the killing ability of cytotoxic drugs make this drug conjugate the ideal one for treatment of various cancers. The success of this technology has become possible only with increasing technological advancements. The potential of a cytotoxic drug embedded in the antibody drug conjugate is increased by 100–1000 fold more than the potential of cytotoxic drug when it acts alone.


The key antibody-drug conjugates currently under the clinical trial is glembatumumab vedotin (CDX-011), a monoclonal antibody-drug conjugate developed by Celldex Therapeutics Inc. Other drugs under clinical trials include Polatuzumab Vedotin (RG7596) developed by Roche/Genentech, Indatuximab Ravtansine (BT-062) developed by Biotest, Anti-guanylyl Cyclase C/Anti-GCC ADC developed by Takeda: Millennium, Anti-PSMA ADC Therapeutics developed by Progenics Pharmaceuticals; Coltuximab Ravtansine (SAR3419) developed by Sanofi, Pinatuzumab Vedotin (RG7593) developed by Roche/Genentech, and Lifastuzumab Vedotin (RG7599) developed by Roche/Genentech.


The advancement in the medical technology is driving the global market for antibody drug conjugates. Moreover, the rising cases of cancer, increase in obese population, and growing ageing population are some of the key driving factors for the market. Further over, preclinical research, the increasing research activities on antibody therapies, more research on advanced drug discoveries, increasing research on oncology diseases, the growing collaboration between research institutes, and biopharmaceuticals and biotechnology companies are acting as a fuel to the market and are expected to drive the market of antibody drug conjugates within the forecast period. However, the high cost of procedures and the lack of fund could be the restraints for the growth of this market.


The antibody drug conjugate market is expected to grow at a CAGR of approximately 19% during the forecast period, 2017–2023.


Research Methodology


 antibody drug conjugate


Sources: Annual reports, Press release, White paper, and Company presentation


Segmentation


The global antibody drug conjugate market is segmented on the basis of type, product, technology, application, and end-user.  


On the basis of type, the global antibody drug conjugate market is segmented into monoclonal antibodies, linker, drug/toxin, and others.


On the basis of application, the global antibody drug conjugate market is segmented into leukemia, prostate cancer, kidney cancer, pancreas cancer, ovary cancer, glioblastoma, lung cancer, colon cancer, breast cancer, skin cancer, solid tumors, multiple myeloma, lymphoma, and other cancers. The leukemia segment is further divided into Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), and Chronic Lymphocytic Leukemia (CLL).


On the basis of product, the global antibody drug conjugate market is segmented into Adcertis, Kadcyla, and others.


On the basis of technology, the global antibody drug conjugate market is classified into ImmunoGen technology, Seattle Genetics technology, Immunomedics technology, and others.


On the basis of end-user, the global antibody drug conjugate market is classified into hospitals, specialized cancer centers, academic research institutes, biotechnology companies, biopharmaceutical companies, and others. 


Regional Analysis


The global antibody drug conjugate market consists of four regions, namely, America, Europe, Asia Pacific, and the Middle East and Africa.


Americas dominated the global antibody drug conjugate market owing to the technological innovation, advancement in manufacturing processes, contribution of nanotechnology for developing Antibody Drug Conjugates (ADC). There are only three antibody drug conjugates that have received approval from the U.S. Food and Drug Administration (FDA). The US is the largest market among other countries such as Mexico, Canada, and others. Though, this technology is being developed by many large pharmaceutical companies, the success rate is of developing an ADC very less and lies with very few companies.


The European antibody drug conjugate market is the second largest market followed by the Asia Pacific regions.


Asia Pacific is the emerging market in the global antibody drug conjugate market. The rising awareness among consumers along with growing government initiatives are driving the antibody drug conjugate market in this region. There are many products under the pipeline. These developments are carried out under license agreements.


Key Players


Some major players in the global antibody drug conjugate market include Seattle Genetics (US), ImmunoGen, Inc. (US), Roche Holding AG (Switzerland), Genentech (US), Concortis Biotherapeutics (US), Agensys, Inc. (US), Antikor (UK), Immunomedics (US), Pfizer Inc. (US), Celldex Therapeutics (US), Millennium Pharmaceuticals (US), AbbVie Inc. (US), Bayer HealthCare (Germany),  Astellas Pharma/Agensys (Japan), Progenics Pharmaceuticals (US), Mersana Therapeutics (US), Synthon (US), Heidelberg Pharma (Germany), Oxford BioTherapeutics (US), and others.


Intended Audience



  • Antibody drug conjugate manufacturing companies

  • Suppliers and distributors of antibody drug conjugate

  • Healthcare service providers

  • Health insurance players

  • Research and consulting firms

  • Medical research institutes

  • Venture capitalists

  • Community centers

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Antibody Drug Conjugate Market, by Type

6.1 Introduction

6.2 Monoclonal Antibodies

6.2.1 Market Estimates & Forecast, 2020-2027

6.3 Linker

6.3.1 Market Estimates & Forecast, 2020-2027

6.4 Drug/Toxin

6.4.1 Market Estimates & Forecast, 2020-2027

6.5 Others

Chapter 7. Global Antibody Drug Conjugate Market, by Application

7.1 Introduction

7.2 Leukemia

7.2.1 Market Estimates & Forecast, 2020-2027

7.2.2 Acute Myeloid Leukemia (AML)

7.2.2.1 Market Estimates & Forecast, 2020-2027

7.2.3 Chronic Myeloid Leukemia (CML)

7.2.3.1 Market Estimates & Forecast, 2020-2027

7.2.4 Acute Lymphocytic Leukemia (ALL)

7.2.4.1 Market Estimates & Forecast, 2020-2027

7.2.5 Chronic Lymphocytic Leukemia (CLL)

7.2.5.1 Market Estimates & Forecast, 2020-2027

7.3 Prostate Cancer

7.3.1 Market Estimates & Forecast, 2020-2027

7.4 Kidney Cancer

7.4.1 Market Estimates & Forecast, 2020-2027

7.5 Pancreas Cancer

7.5.1 Market Estimates & Forecast, 2020-2027

7.6 Ovary Cancer

7.6.1 Market Estimates & Forecast, 2020-2027

7.7 Glioblastoma

7.7.1 Market Estimates & Forecast, 2020-2027

7.8 Lung Cancer

7.8.1 Market Estimates & Forecast, 2020-2027

7.9 Colon Cancer

7.9.1 Market Estimates & Forecast, 2020-2027

7.10 Breast Cancer

7.10.1 Market Estimates & Forecast, 2020-2027

7.11 Skin Cancer

7.11.1 Market Estimates & Forecast, 2020-2027

7.12 Solid Tumors

7.12.1 Market Estimates & Forecast, 2020-2027

7.13 Multiple Myeloma

7.13.1 Market Estimates & Forecast, 2020-2027

7.14 Lymphoma

7.14.1 Market Estimates & Forecast, 2020-2027

7.15 Others

Chapter 8. Global Antibody Drug Conjugate Market, by Product

8.1 Introduction

8.2 Adcertis

8.2.1 Market Estimates & Forecast, 2020-2027

8.3 Kadcyla

8.3.1 Market Estimates & Forecast, 2020-2027

8.4 Others

Chapter 9. Global Antibody Drug Conjugate Market, by Technology

9.1 Introduction

9.2 ImmunoGen technology

9.2.1 Market Estimates & Forecast, 2020-2027

9.3 Seattle Genetics technology

9.3.1 Market Estimates & Forecast, 2020-2027

9.4 Immunomedics technology

9.4.1 Market Estimates & Forecast, 2020-2027

9.4 Others

Chapter 10. Global Antibody Drug Conjugate Market, by End-User

10.1 Introduction

10.2 Hospitals

10.2.1 Market Estimates & Forecast, 2020-2027

10.3 Specialized Cancer Centers

10.3.1 Market Estimates & Forecast, 2020-2027

10.4 Academic Research Institutes

10.4.1 Market Estimates & Forecast, 2020-2027

10.5 Biopharmaceutical Companies

10.5.1 Market Estimates & Forecast, 2020-2027

10.6 Others

Chapter. 11 Global Antibody Drug Conjugate Market, by Region

11.1 Introduction

11.2 Americas

11.2.1 North America

11.2.1.1 U.S.

11.2.1.1 Canada

11.2.2 South America

11.3 Europe

11.3.1 Western Europe

11.3.1.1 Germany

11.3.1.2 France

11.3.1.3 Italy

11.3.1.4 Spain

11.3.1.5 U.K.

11.3.1.6 Rest of Western Europe

11.3.2 Eastern Europe

11.4 Asia Pacific

11.4.1 Japan

11.4.2 China

11.4.3 India

11.4.4 Australia

11.4.5 Republic of Korea

11.4.6 Rest of Asia Pacific

11.5 The Middle East & Africa

11.5.1 United Arab Emirates

11.5.2 Saudi Arabia

11.5.3 Rest of the Middle East & Africa

Chapter 12 Company Landscape

12.1 Introduction

12.2 Market Share Analysis

12.3 Key Development & Strategies

12.3.1 Key Developments

Chapter 13 Company Profiles

13.1 Seattle Genetics

13.1.1 Company Overview

13.1.2 Product Overview

13.1.3 Financials

13.1.4 SWOT Analysis

13.2 ImmunoGen, Inc.

13.2.1 Company Overview

13.2.2 Product Overview

13.2.3 Financial Overview

13.2.4 Key Developments

13.2.5 SWOT Analysis

13.3 Roche Holding AG

13.3.1 Company Overview

13.3.2 Product Overview

13.3.3 Financial Overview

13.3.4 Key Development

13.3.5 SWOT Analysis

13.4 Genentech

13.4.1 Company Overview

13.4.2 Product/Business Segment Overview

13.4.3 Financial Overview

13.4.4 Key Development

13.4.5 SWOT Analysis

13.5 Concortis Biotherapeutics

13.5.1 Company Overview

13.5.2 Product Overview

13.5.3 Financial overview

13.5.4 Key Developments

13.6 AGENSYS, INC.

13.6.1 Company Overview

13.6.2 Product Overview

13.6.3 Financial Overview

13.6.4 Key Developments

13.7 Antikor

13.7.1 Overview

13.7.2 Product Overview

13.7.3 Financials

13.7.4 Key Developments

13.7.5 SWOT Analysis

13.8 Immunomedics

13.8.1 Company Overview

13.8.2 Product/Business Segment Overview

13.8.3 Financial Overview

13.8.4 Key Development

13.8.5 SWOT Analysis

13.9 Pfizer Inc.

13.9.1 Company Overview

13.9.2 Product Overview

13.9.3 Financial overview

13.9.4 Key Developments

13.10 Others

Chapter 14 MRFR Conclusion

14.1 Key Findings

14.1.1 From CEO’s View Point

14.1.2 Unmet Needs of the Market

14.2 Key Companies to Watch

14.3 Prediction of the Pharmaceutical Industry

Chapter 15 Appendix


LIST OF TABLES

Table 1 Antibody Drug Conjugate Industry Synopsis, 2020-2027

Table 2 Antibody Drug Conjugate Market Estimates & Forecast, 2020-2027, (USD Million)

Table 3 Antibody Drug Conjugate Market, by Region, 2020-2027, (USD Million)

Table 4 Antibody Drug Conjugate Market, by Type, 2020-2027, (USD Million)

Table 5 Antibody Drug Conjugate Market, by Application, 2020-2027, (USD Million)

Table 6 Antibody Drug Conjugate Market, by Product, 2020-2027, (USD Million)

Table 7 Antibody Drug Conjugate Market, by Technology, 2020-2027, (USD Million)

Table 8 Antibody Drug Conjugate Market, by End-User, 2020-2027, (USD Million)

Table 9 North America Antibody Drug Conjugate Market, by Type, 2020-2027, (USD Million)

Table 10 North America Antibody Drug Conjugate Market, by Application, 2020-2027, (USD Million)

Table 11 North America Antibody Drug Conjugate Market, by Product, 2020-2027, (USD Million)

Table 12 North America Antibody Drug Conjugate Market, by Technology, 2020-2027, (USD Million)

Table 13 North America Antibody Drug Conjugate Market, by End-User, 2020-2027, (USD Million)

Table 14 U.S. Antibody Drug Conjugate Market, by Type, 2020-2027, (USD Million)

Table 15 U.S. Antibody Drug Conjugate Market, by Application, 2020-2027, (USD Million)

Table 16 U.S. Antibody Drug Conjugate Market, by Product, 2020-2027, (USD Million)

Table 17 U.S. Antibody Drug Conjugate Market, by Technology, 2020-2027, (USD Million)

Table 18 U.S. Antibody Drug Conjugate Market, by End-User, 2020-2027, (USD Million)

Table 19 Canada Antibody Drug Conjugate Market, by Type, 2020-2027, (USD Million)

Table 20 Canada Antibody Drug Conjugate Market, by Application, 2020-2027, (USD Million)

Table 21 Canada Antibody Drug Conjugate Market, by Product, 2020-2027, (USD Million)

Table 22 Canada Antibody Drug Conjugate Market, by Technology, 2020-2027, (USD Million)

Table 23 Canada Antibody Drug Conjugate Market, by End-User, 2020-2027, (USD Million)

Table 24 South America Antibody Drug Conjugate Market, by Type, 2020-2027, (USD Million)

Table 25 South America Antibody Drug Conjugate Market, by Application, 2020-2027, (USD Million)

Table 26 South America Antibody Drug Conjugate Market, by Product, 2020-2027, (USD Million)

Table 27 South America Antibody Drug Conjugate Market, by Technology, 2020-2027, (USD Million)

Table 28 South America Antibody Drug Conjugate Market, by End-User, 2020-2027, (USD Million)

Table 29 Europe Antibody Drug Conjugate Market, by Type, 2020-2027, (USD Million)

Table 30 Europe Antibody Drug Conjugate Market, by Application, 2020-2027, (USD Million)

Table 31 Europe Antibody Drug Conjugate Market, by Product, 2020-2027, (USD Million)

Table 32 Europe Antibody Drug Conjugate Market, by Technology, 2020-2027, (USD Million)

Table 33 Europe Antibody Drug Conjugate Market, by End-User, 2020-2027, (USD Million)

Table 34 Western Europe Antibody Drug Conjugate Market, by Type, 2020-2027, (USD Million)

Table 35 Western Europe Antibody Drug Conjugate Market, by Application, 2020-2027, (USD Million)

Table 36 Western Europe Antibody Drug Conjugate Market, by Product, 2020-2027, (USD Million)

Table 37 Western Europe Antibody Drug Conjugate Market, by Technology, 2020-2027, (USD Million)

Table 38 Western Europe Antibody Drug Conjugate Market, by End-User, 2020-2027, (USD Million)

Table 39 Eastern Europe Antibody Drug Conjugate Market, by Type, 2020-2027, (USD Million)

Table 40 Eastern Europe Antibody Drug Conjugate Market, by Application, 2020-2027, (USD Million)

Table 41 Eastern Europe Antibody Drug Conjugate Market, by Product, 2020-2027, (USD Million)

Table 42 Eastern Europe Antibody Drug Conjugate Market, by Technology, 2020-2027, (USD Million)

Table 43 Eastern Europe Antibody Drug Conjugate Market, by End-User, 2020-2027, (USD Million)

Table 44 Asia Pacific Antibody Drug Conjugate Market, by Type, 2020-2027, (USD Million)

Table 45 Asia Pacific Antibody Drug Conjugate Market, by Application, 2020-2027, (USD Million)

Table 46 Asia Pacific Antibody Drug Conjugate Market, by Product, 2020-2027, (USD Million)

Table 47 Asia Pacific Antibody Drug Conjugate Market, by Technology, 2020-2027, (USD Million)

Table 48 Asia Pacific Antibody Drug Conjugate Market, by End-User, 2020-2027, (USD Million)

Table 49 The Middle East & Africa Antibody Drug Conjugate Market, by Type, 2020-2027, (USD Million)

Table 50 The Middle East & Africa Antibody Drug Conjugate Market, by Application, 2020-2027, (USD Million)

Table 51 The Middle East & Africa Antibody Drug Conjugate Market, by Product, 2020-2027, (USD Million)

Table 52 The Middle East & Africa Antibody Drug Conjugate Market, by Technology, 2020-2027, (USD Million)

Table 53 The Middle East & Africa Antibody Drug Conjugate Market, by End-User, 2020-2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Antibody Drug Conjugate Market

Figure 3 Segmentation Market Dynamics for Antibody Drug Conjugate Market

Figure 4 Global Antibody Drug Conjugate Market Share, by Type, 2020

Figure 5 Global Antibody Drug Conjugate Market Share, by Application, 2020

Figure 6 Global Antibody Drug Conjugate Market Share, by Product, 2020

Figure 8 Global Antibody Drug Conjugate Market Share, by Technology, 2020

Figure 9 Global Antibody Drug Conjugate Market Share, by End-User, 2020

Figure 10 Global Antibody Drug Conjugate Market Share, by Region, 2020

Figure 11 North America Antibody Drug Conjugate Market Share, by Country, 2020

Figure 12 Europe Antibody Drug Conjugate Market Share, by Country, 2020

Figure 13 Asia Pacific Antibody Drug Conjugate Market Share, by Country, 2020

Figure 14 The Middle East & Africa Antibody Drug Conjugate Market Share, by Country, 2020

Figure 15 Global Antibody Drug Conjugate Market: Company Share Analysis, 2020 (%)

Figure 16 Seattle Genetics: Key Financials

Figure 17 Seattle Genetics: Segmental Revenue

Figure 18 Seattle Genetics: Geographical Revenue

Figure 19 ImmunoGen, Inc.: Key Financials

Figure 20 ImmunoGen, Inc.: Segmental Revenue

Figure 21 ImmunoGen, Inc.: Geographical Revenue

Figure 22 Roche Holding AG: Key Financials

Figure 23 Roche Holding AG: Segmental Revenue

Figure 24 Roche Holding AG: Geographical Revenue

Figure 25 Genentech: Key Financials

Figure 26 Genentech: Segmental Revenue

Figure 27 Genentech: Geographical Revenue

Figure 28 Concortis Biotherapeutics: Key Financials

Figure 29 Concortis Biotherapeutics: Segmental Revenue

Figure 30 Concortis Biotherapeutics: Geographical Revenue

Figure 32 AGENSYS, INC.: Key Financials

Figure 33 AGENSYS, INC.: Segmental Revenue

Figure 34 AGENSYS, INC.: Geographical Revenue

Figure 35 Antikor: Key Financials

Figure 36 Antikor: Segmental Revenue

Figure 37 Antikor: Geographical Revenue

Figure 38 Immunomedics: Key Financials

Figure 39 Immunomedics: Segmental Revenue

Figure 40 Immunomedics: Geographical Revenue

Figure 41 Pfizer Inc.: Key Financials

Figure 42 Pfizer Inc.: Segmental Revenue

Figure 43 Pfizer Inc.: Geographical Revenue

Antibody Drug Conjugate Market